LLY241206C970000
- 0.85
- 0.000.00%
Eli Lilly and Co Newsroom
Eli Lilly (LLY.US) outperformed Novo Nordisk (NVO.US) in the comparative trial showing that Zepbound is superior to Wegovy.
Eli Lilly and Co (LLY.US) announced that its weight loss drug Zepbound performed better in the first head-to-head trial compared to the competitor novo-nordisk a/s (NVO.US) Wegovy.
Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy in First Head-to-Head Study
Express News | Eli Lilly Shares up 1.3% Premarket After Co's Weight-Loss Drug Tops Rival Wegovy in Head-to-Head Study
Express News | Eli Lilly Announced Topline Results From The SURMOUNT-5 Phase 3b Open-label Randomized Clinical Trial
Express News | Lilly: At 72 Weeks, Zepbound Beat Wegovy on Both Primary Endpoint, All Five Key Secondary Endpoints in Trial
Express News | Lilly's Zepbound (Tirzepatide) Superior to Wegovy (Semaglutide) in Head-to-Head Trial Showing an Average Weight Loss of 20.2% Vs. 13.7%
Express News | Lilly: In Phase 3B Trial, Zepbound Provided a 47% Greater Relative Weight Loss Vs Wegovy
Express News | Lilly: In Phase 3B Trial, Participants Using Zepbound Lost 50.3 Lbs. (22.8 Kg) and Participants on Wegovy Lost 33.1 Lbs. (15.0 Kg)
Express News | Lilly: Commonly Reported Adverse Events in Surmount-5 for Zepbound & Wegovy Were Gastrointestinal-Related, Generally Mild to Moderate in Severity
Lilly's Zepbound (Tirzepatide) Superior to Wegovy (Semaglutide) in Head-to-head Trial Showing an Average Weight Loss of 20.2% Vs. 13.7%
Fresh Closing Highs from S&P 500 and Nasdaq | Wall Street Today
BeiGene Started at Overweight at Morgan Stanley on Brukinsa Market Share Growth
Express News | 'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape
Tuesday S&P 500 Pulls Back From Highs, Nasdaq Climbs | Live Stock
Sector Update: Health Care Stocks Decline Premarket Tuesday
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
Market Chatter: Novo Nordisk's India Executives Push for Wegovy Launch in 2025
Concerned about falling behind eli lilly and co (LLY.US) and novo-nordisk a/s (NVO.US), the team in india urges to launch Wegovy in india as soon as possible.
Due to concerns about falling behind competitor eli lilly and co in the potentially huge market in india, the indian team of the danish pharmaceutical giant novo-nordisk a/s has been pushing for the earlier launch of its popular weight-loss drug Wegovy in india.
S&P 500 and Nasdaq Hit Closing and Trading Highs Monday | Wall Street Today